(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Ventyx Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VTYX's revenue for 2026 to be $6,484,875,271, with the lowest VTYX revenue forecast at $6,484,875,271, and the highest VTYX revenue forecast at $6,484,875,271. On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $16,774,691,532, with the lowest VTYX revenue forecast at $183,847,734, and the highest VTYX revenue forecast at $33,365,535,331.
In 2028, VTYX is forecast to generate $29,180,170,951 in revenue, with the lowest revenue forecast at $579,827,469 and the highest revenue forecast at $57,780,514,432.